The FDA accepted Regeneron’s BLA resubmission for linvoseltamab in relapsed or refractory multiple myeloma, with a decision ...

The PDUFA action date for an FDA decision for linvoseltamab to treat adult patients with relapsed/refractory multiple myeloma ...

The off-the-shelf chimeric antigen receptor T-cell therapy P-BCMA-ALLO1 was shown to be safe and elicited strong anti-tumor ...

Black Americans have double the risk of developing multiple myeloma compared to white Americans and are diagnosed at younger ages.

During a Case-Based Roundtable® event, Muhammad Umair Mushtaq, MD, discussed managing long-term toxicity concerns related to ...

Regardless of the many new treatment modalities being developed for myeloma, it is still a disease that is accompanied by consistent relapses and according to one source, led to an estimated 117,077 ...

Researchers sought to identify prognostic factors for survival in patients with newly diagnosed multiple myeloma.

The researchers also projected that newly diagnosed MM cases will increase by 70.8% by 2045 — from about 188,000 cases in 2022 to about 321,000 cases in 2045. The number of deaths due to MM is ...

Carvykti and Abecma could soon have new competition from Gilead Sciences and partner Arcellx, which in November 2024 touted strong response rates and promising survival outcomes from a registrational ...